SURGERY PARTNERS INC (NASDAQ:SGRY) reported its second-quarter 2025 earnings, delivering mixed results relative to analyst expectations. The company posted revenue of $826.2 million, falling short of the consensus estimate of $833.3 million. However, earnings per share (EPS) came in at $0.17, surpassing the projected $0.1369. The market reaction has been cautiously positive, with pre-market trading showing a modest uptick of approximately 0.56%, suggesting investors are weighing the earnings beat against the revenue miss.
Key Takeaways from the Earnings Report
- Revenue Miss: The company reported $826.2 million in Q2 revenue, slightly below the $833.3 million analysts had anticipated.
- EPS Beat: Adjusted EPS of $0.17 exceeded expectations by $0.0331, reflecting stronger-than-expected profitability despite lower revenue.
- Reaffirmed Guidance: Management reiterated its full-year 2025 outlook, aligning with analyst expectations for revenue and earnings.
Market Reaction
The stock’s pre-market gain of 0.56% indicates a tempered but positive response to the earnings release. Over the past month, shares have seen minimal movement, with a slight increase of 0.84%, while weekly performance remains nearly flat (-1%). The EPS beat appears to be the primary driver of the early market reaction, though the revenue shortfall may limit upside momentum.
Looking Ahead
Analysts estimate Q3 2025 revenue at $851.03 million, with full-year sales projected at $3.443 billion. The company’s reaffirmed guidance suggests confidence in meeting these targets, though investors will be watching for improved top-line growth in the coming quarters.
For a deeper dive into SURGERY PARTNERS INC’s earnings and estimates, visit the earnings page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
